Neratinib plus fulvestrant plus trastuzumab for hormone receptor-positive, HER2-mutant metastatic breast cancer and neratinib plus trastuzumab for triple-negative disease: Latest updates from the SUMMIT trial

CANCER RESEARCH(2022)

引用 0|浏览6
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要